MITOCAREX BIO

MitoCareX Bio was founded in 2022 with the goal to utilize its computational chemistry knowledge and know how in the field of Mitochondrial Carriers in order to develop new transformative medicines... However, despite being directly linked with severe pathologies, the number of drug discovery projects in the field is still very low, and Computer Aided Drug Design (CADD) campaigns are scarce due to the limited amount of solved 3D structures (i.e., solved 3D structures are only available for the non-H. sapiens ADP/ATP carrier). To discover new potential drugs targeting human mitochondrial carriers, MitoCareX Bio has developed its MITOLINE™ algorithm and other advanced computational capabilities to generate reliable 3D models for its mitochondrial proteins of interest - a major key step for utilizing CADD. To recognize novel small molecule scaffolds interacting with our proteins of interest, we use our advanced cloud-based computational platform to efficiently screen numerous small..

Also known as: MitoCareX Bio Ltd.